Cargando…
Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with skin tropism. The entity was recently defined and the diagnosis is generally made by skin biopsies. It is necessary to apply appropriate immunohistochemistry to recognize this rare entity. There is no consensus on therapy...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057751/ https://www.ncbi.nlm.nih.gov/pubmed/31752482 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0195 |
_version_ | 1783503729652137984 |
---|---|
author | Demiröz, Ahu Senem Demirkesen, Cuyan Salihoğlu, Ayşe Tüzüner, Nükhet |
author_facet | Demiröz, Ahu Senem Demirkesen, Cuyan Salihoğlu, Ayşe Tüzüner, Nükhet |
author_sort | Demiröz, Ahu Senem |
collection | PubMed |
description | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with skin tropism. The entity was recently defined and the diagnosis is generally made by skin biopsies. It is necessary to apply appropriate immunohistochemistry to recognize this rare entity. There is no consensus on therapy and the survival rates are low. The aim of this study is to describe the clinical and histopathological features of BPDCN. We retrospectively reviewed 8 BPDCN cases of the Cerrahpaşa Medical Faculty diagnosed between 2005 and 2019. We documented the clinical findings, histopathologic diagnoses, and outcomes. The mean age of the patients was 58.7 years (range=11-86 years), and 7 patients were male. The patients presented with erythematous or purple papules, plaques, and papulonodular or nodular cutaneous lesions. Two had lymphadenomegaly at presentation. In microscopic evaluations, tumor cells infiltrated the entire dermis with a clear-cut subepidermal Grenz zone in all cases. CD4, CD56, and CD123 were the most frequently expressed immunohistochemical markers. The median follow-up of 7 cases was 14 months, ranging from 6 to 48 months. Three patients died of the disease, while 4 patients were still alive. Out of 7 patients, 5 received chemotherapy. We found that the outcomes of some patients were different from others but we did not link any distinct clinical or histopathological characteristics to these different outcomes. |
format | Online Article Text |
id | pubmed-7057751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-70577512020-03-16 Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience Demiröz, Ahu Senem Demirkesen, Cuyan Salihoğlu, Ayşe Tüzüner, Nükhet Turk J Haematol Brief Report Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy with skin tropism. The entity was recently defined and the diagnosis is generally made by skin biopsies. It is necessary to apply appropriate immunohistochemistry to recognize this rare entity. There is no consensus on therapy and the survival rates are low. The aim of this study is to describe the clinical and histopathological features of BPDCN. We retrospectively reviewed 8 BPDCN cases of the Cerrahpaşa Medical Faculty diagnosed between 2005 and 2019. We documented the clinical findings, histopathologic diagnoses, and outcomes. The mean age of the patients was 58.7 years (range=11-86 years), and 7 patients were male. The patients presented with erythematous or purple papules, plaques, and papulonodular or nodular cutaneous lesions. Two had lymphadenomegaly at presentation. In microscopic evaluations, tumor cells infiltrated the entire dermis with a clear-cut subepidermal Grenz zone in all cases. CD4, CD56, and CD123 were the most frequently expressed immunohistochemical markers. The median follow-up of 7 cases was 14 months, ranging from 6 to 48 months. Three patients died of the disease, while 4 patients were still alive. Out of 7 patients, 5 received chemotherapy. We found that the outcomes of some patients were different from others but we did not link any distinct clinical or histopathological characteristics to these different outcomes. Galenos Publishing 2020-03 2020-02-20 /pmc/articles/PMC7057751/ /pubmed/31752482 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0195 Text en © Copyright 2020 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Demiröz, Ahu Senem Demirkesen, Cuyan Salihoğlu, Ayşe Tüzüner, Nükhet Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience |
title | Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience |
title_full | Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience |
title_fullStr | Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience |
title_full_unstemmed | Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience |
title_short | Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience |
title_sort | blastic plasmacytoid dendritic cell neoplasia: a single center experience |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057751/ https://www.ncbi.nlm.nih.gov/pubmed/31752482 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0195 |
work_keys_str_mv | AT demirozahusenem blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience AT demirkesencuyan blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience AT salihogluayse blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience AT tuzunernukhet blasticplasmacytoiddendriticcellneoplasiaasinglecenterexperience |